Market Overview

Personalised Medicine - Global Technologies & Market Share (2017-2024): CAGR to Grow at 12% -


The "Global
Personalised Medicine Market - Technologies, Market share and Industry
Forecast to 2024"
report has been added to's

Global personalized medicine market is expected to rise with a CAGR of
12% over the forecast period 2017-2024.

Key factors driving the market growth are rising prevalence of cancer,
development of novel drugs, growth in biotechnology sector and growing
number of companion/associated diagnostics.

Stringent government regulations regarding product approval and high
development costs are expected to restrain the market growth. However,
increasing healthcare expenditure and favorable government policies and
initiatives are expected to provide lucrative market opportunities.

Complex nature of the drugs and presence of non-value based personalized
medicine diagnostics reimbursement policy is expected to challenge the
market growth.

Key Highlights

  • On the basis of therapeutic area, neurology is the leading therapeutic
    area segment owing to the increase in research and development
    activities for the development of novel precision medicines for the
    cost-effective treatment of neurological disorders.
  • On the basis of end-user, hospitals is the dominating end-user segment
    due to the increased adoption of personalized medicines by the
    hospital patients for low cost personalized treatment.
  • On the basis of applications, biomarker identification is the leading
    application segment due to increased adoption of personalized
    medicines for the identification genes specific to the disease
    subtypes which would assist in the estimation of disease risk and
    therapy response.

Key Topics Covered

1. Introduction

2. Market Overview

3. Market Determinants

4. Global Personalized Medicine Market, by Therapeutic Area

5. Global Personalized Medicine Market, by End-User

6. Global Personalized Medicine Market, by Application

7. Competitive Landscape

8. Geographic Analysis

9. Company Profiles

  • Abbott Laboratories (U.S.)
  • Astra Zeneca PLC (UK)
  • Asuragen Incorporated (UK)
  • Becton, Dickinson and Company (U.S.)
  • Biogen Inc. (U.S.)
  • GE Healthcare (U.S.)
  • Glaxosmithkline PLC (UK)
  • Illumina Incorporated (U.S.)
  • Merck & Company Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S.)
  • Qiagen Inc. (The Netherlands)
  • Roche Holding AG (Switzerland)
  • Siemens Healthcare (Germany)
  • Vertex Pharmaceuticals Inc. (UK)

For more information about this report visit

View Comments and Join the Discussion!